Health Care • Medicinal Chemicals and Botanical Products
$76.75 ▲ +3.76
(+5.15%)
MKT CAP: $128.15B • VOL: 12.53M
52W L $55 52W H $80
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$64
MEDIAN
$86
MEAN
$87
HIGH
$104
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MO TAPE
MO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $92.87 | $88.26 | 2025-02-14 | $69.84 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $96.70 | $90.56 | 2025-02-06 | $72.14 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $87.49 | $84.43 | 2025-01-29 | $73.68 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $78.28 | — | 2025-01-17 | $75.22 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $67.54 | $72.91 | 2025-01-09 | $68.31 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $91.33 | $79.82 | 2024-12-18 | $66.77 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $74.45 | $77.52 | 2024-12-04 | $71.38 | -4.3% | 48% | C |